Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15

1.

Lack of ephrin receptor A1 is a favorable independent prognostic factor in clear cell renal cell carcinoma.

Toma MI, Erdmann K, Diezel M, Meinhardt M, Zastrow S, Fuessel S, Wirth MP, Baretton GB.

PLoS One. 2014 Jul 15;9(7):e102262. doi: 10.1371/journal.pone.0102262. eCollection 2014.

2.

PARK2 and PACRG are commonly downregulated in clear-cell renal cell carcinoma and are associated with aggressive disease and poor clinical outcome.

Toma MI, Wuttig D, Kaiser S, Herr A, Weber T, Zastrow S, Koch R, Meinhardt M, Baretton GB, Wirth MP, Fuessel S.

Genes Chromosomes Cancer. 2013 Mar;52(3):265-73. doi: 10.1002/gcc.22026. Epub 2012 Nov 2.

PMID:
23125027
3.

CD31, EDNRB and TSPAN7 are promising prognostic markers in clear-cell renal cell carcinoma revealed by genome-wide expression analyses of primary tumors and metastases.

Wuttig D, Zastrow S, Füssel S, Toma MI, Meinhardt M, Kalman K, Junker K, Sanjmyatav J, Boll K, Hackermüller J, Rolle A, Grimm MO, Wirth MP.

Int J Cancer. 2012 Sep 1;131(5):E693-704. doi: 10.1002/ijc.27419. Epub 2012 Feb 28.

4.

Expression of the Forkhead transcription factor FOXP1 is associated with tumor grade and Ki67 expression in clear cell renal cell carcinoma.

Toma MI, Weber T, Meinhardt M, Zastrow S, Grimm MO, Füssel S, Wirth MP, Baretton GB.

Cancer Invest. 2011 Feb;29(2):123-9. doi: 10.3109/07357907.2010.535059. Epub 2011 Jan 6.

PMID:
21210727
5.

Correlation of centrosomal aberrations with cell differentiation and DNA ploidy in prostate cancer.

Toma MI, Friedrich K, Meyer W, Fröhner M, Schneider S, Wirth M, Baretton GB.

Anal Quant Cytol Histol. 2010 Feb;32(1):1-10.

PMID:
20701082
6.

Loss of heterozygosity and copy number abnormality in clear cell renal cell carcinoma discovered by high-density affymetrix 10K single nucleotide polymorphism mapping array.

Toma MI, Grosser M, Herr A, Aust DE, Meye A, Hoefling C, Fuessel S, Wuttig D, Wirth MP, Baretton GB.

Neoplasia. 2008 Jul;10(7):634-42.

7.

The role of the endothelin axis and microvessel density in bladder cancer - correlation with tumor angiogenesis and clinical prognosis.

Herrmann E, Bögemann M, Bierer S, Eltze E, Toma MI, Köpke T, Hertle L, Wülfing C.

Oncol Rep. 2007 Jul;18(1):133-8.

PMID:
17549358
8.

[DNA methylation on urinalysis and as a prognostic marker in urothelial cancer of the bladder].

Friedrich MG, Toma MI, Chun JK, Steuber T, Budäus L, Isbarn H, Huland H.

Urologe A. 2007 Jul;46(7):761-8. German.

PMID:
17522834
9.

Prognostic relevance of methylation markers in patients with non-muscle invasive bladder carcinoma.

Friedrich MG, Chandrasoma S, Siegmund KD, Weisenberger DJ, Cheng JC, Toma MI, Huland H, Jones PA, Liang G.

Eur J Cancer. 2005 Nov;41(17):2769-78. Epub 2005 Oct 19.

PMID:
16242928
10.

Detection of methylated apoptosis-associated genes in urine sediments of bladder cancer patients.

Friedrich MG, Weisenberger DJ, Cheng JC, Chandrasoma S, Siegmund KD, Gonzalgo ML, Toma MI, Huland H, Yoo C, Tsai YC, Nichols PW, Bochner BH, Jones PA, Liang G.

Clin Cancer Res. 2004 Nov 15;10(22):7457-65.

11.

Expression of Maspin in non-muscle invasive bladder carcinoma: correlation with tumor angiogenesis and prognosis.

Friedrich MG, Toma MI, Petri S, Cheng JC, Hammerer P, Erbersdobler A, Huland H.

Eur Urol. 2004 Jun;45(6):737-43.

PMID:
15149745
12.

Comparison of the ImmunoCyt test and urinary cytology with other urine tests in the detection and surveillance of bladder cancer.

Toma MI, Friedrich MG, Hautmann SH, Jäkel KT, Erbersdobler A, Hellstern A, Huland H.

World J Urol. 2004 Jun;22(2):145-9. Epub 2004 Feb 27.

PMID:
14991320
13.

Comparison of multitarget fluorescence in situ hybridization in urine with other noninvasive tests for detecting bladder cancer.

Friedrich MG, Toma MI, Hellstern A, Pantel K, Weisenberger DJ, Noldus J, Huland H.

BJU Int. 2003 Dec;92(9):911-4.

14.
15.

Are false-positive urine markers for the detection of bladder carcinoma really wrong or do they predict tumor recurrence?

Friedrich MG, Hellstern A, Toma MI, Hammerer P, Huland H.

Eur Urol. 2003 Feb;43(2):146-50; discussion 150-1.

PMID:
12565772

Supplemental Content

Support Center